ProtonDx Analysis: $11M Raised
What is ProtonDx?
ProtonDx develops portable, rapid molecular testing devices using proprietary LAMP technology. Their lab-on-a-chip systems enable multi-pathogen detection with high sensitivity and speed. The company was spun out of Imperial College London in 2020 and has received multiple awards including the IEEE CASS COVID-19 Entrepreneur’s Award and the IET Mike Sergeant Achievement Medal.
Location
London, United Kingdom
Employees
11-50
Founded
2020
Funding Status
Series A
Product Features & Capabilities
- Dragonfly device for human pathogen detection
- SmartLid for rapid nucleic acid extraction
- TurboBeads for enhanced sample processing
- Solvent-free wash buffer for clean sample preparation
- LyoLAMP for portable molecular testing
Use Cases
Detect respiratory viruses in point-of-care settings; Perform pathogen screening in animal health clinics; Enable rapid diagnostics in life sciences research labs; Extract nucleic acids from clinical samples in under 10 minutes; Support multi-pathogen testing in field environments
Other Considerations
Spun out of Imperial College London in 2020; Awarded IEEE CASS COVID-19 Entrepreneur’s Award; Awarded IET Mike Sergeant Achievement Medal; Recognized with Rosetrees Trust Interdisciplinary Prize; Recognized with Wellcome Trust Innovator Award; Received two Imperial Techcelerate Awards; Awarded MedTech SuperConnector Award; Multiple IEEE awards
See something that needs updating? Suggest edits to this profile.